Folinic acid therapy fails to improve early Parkinson's disease: a two week placebo controlled clinical trial.
Folinic acid (15 mg bid, po) was administered in a two week, double-blind, placebocontrolled, cross over clinical trial in 5 patients with Parkinson's disease (Hoehn and Yahr stage I or II). 4 patients had not been on L-dopa treatment prior to entering this trial and one patient was on a small dose of L-dopa. No significant improvement could be detected in this pilot study by clinical evaluation and motor performance assessed by a computer assisted motor performance test.
Schwarz
J
J
Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilian-University, Munich, Federal Republic of Germany.
Trenkwalder
C
C
Gasser
T
T
Arnold
G
G
Oertel
W H
WH
D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000523:psychology; D011597:Psychomotor Performance / Q000187:drug effects
D002955:Leucovorin